Elekta AB (publ) (EKTA B.ST) Azione Prezzo

Elekta AB (publ) Prezzo

OMX·CHIUSO
60,60
​
Mercato chiuso

Il fatturato è cresciuto a un tasso composto del 7,1% annuo negli ultimi 19 anni, raggiungendo 16,72 miliardi SEK. L'utile per azione è diminuito del 2,1% all'anno negli ultimi 18 anni. Il margine netto di Elekta AB (publ) si attesta al -3,1%, in calo rispetto al 7,9% di alcuni anni fa. Elekta AB (publ) offre attualmente un rendimento da dividendo di circa il 3,96%. Il payout ratio è pari a circa il 185% degli utili. Il dividendo è cresciuto del 12,6% all'anno negli ultimi 19 anni. Gli analisti fissano un target di prezzo mediano di 54,06 SEK, ovvero il 10,8% sotto il prezzo attuale. Su 21 analisti, 5 valutano il titolo come acquisto — nel complesso un consenso Vendere.

Elekta AB (publ) Prezzo delle azioni

Accedi a questi dati tramite l’API Eulerpool

100.000 richieste/mese gratis · nessuna carta di credito

Elekta AB (publ) Azione e analisi azionaria

Elekta AB (publ) è un'azienda globale specializzata nello sviluppo, nella produzione e nel marketing di dispositivi medici e sistemi per la radioterapia e la neuromedicina. Fondata in Svezia nel 1972, ha sede a Stoccolma.

Domande frequenti sull'azione Elekta AB (publ)

Elekta AB (publ) is a global medical technology company that specializes in developing and marketing innovative solutions for cancer and brain disorders. The company's business model revolves around providing advanced radiotherapy, stereotactic radiosurgery, and precision radiation medicine systems and software to healthcare providers worldwide. Elekta AB (publ) operates through two primary segments: Radiation Therapy and Magnetic Resonance Imaging (MRI). By offering cutting-edge equipment, software, and clinical management for precise treatment planning and delivery, Elekta AB (publ) aims to improve patient outcomes and enhance the overall efficiency of cancer care. This commitment to technological advancements and medical excellence positions Elekta AB (publ) as a leader in the field of radiation therapy.

Elekta AB (publ) is primarily active in the medical technology industry.

The main competitors of Elekta AB (publ) in the market include Varian Medical Systems, Accuray Incorporated, and Siemens Healthineers.

Elekta AB (publ) is a renowned company with a rich history and background. Established in 1972, Elekta specializes in developing advanced technology and comprehensive treatment solutions for cancer and brain disorders. Headquartered in Stockholm, Sweden, the company has expanded globally, with a presence in more than 100 countries. Elekta's innovation in radiation therapy, radiosurgery, and brachytherapy has revolutionized medical procedures, improving patient outcomes worldwide. With a commitment to precision and innovation, Elekta continues to collaborate with leading experts in healthcare, offering state-of-the-art solutions to enhance the quality of patient care and contribute to life-saving advancements in the field of oncology and neurosurgery. Overall, Elekta AB (publ) is a leading force in the medical technology sector, dedicated to transforming cancer care and neurological treatments.

Elekta AB (publ) has achieved several significant milestones in its trajectory. Over the years, the company has pioneered innovative solutions in the field of radiation therapy and precise neurosurgery. Elekta AB (publ) introduced the revolutionary Elekta Synergy, a state-of-the-art radiation treatment system that enables accurate targeting of tumors while minimizing damage to surrounding healthy tissues. Furthermore, the company developed the Leksell Gamma Knife, a non-invasive radiosurgery system for treating brain disorders with exceptional precision. Elekta AB (publ) continues to expand its global presence and collaborate with leading healthcare institutions, solidifying its position as a trusted provider of advanced medical technology solutions.

Elekta AB (publ) is primarily present in various countries and regions around the world. The company has a global presence, with a strong focus in North America, Europe, and Asia Pacific. Elekta AB (publ) operates in numerous countries, including the United States, Sweden (where it is headquartered), Germany, the United Kingdom, France, China, Australia, and many others. With its innovative medical technology solutions, Elekta AB (publ) continues to expand its presence and serve customers in the healthcare industry across diverse regions, making a significant impact in the field of radiation therapy and neurosurgery.

Elekta AB (publ) represents a company philosophy centered around innovation, quality, and patient care. With a dedicated focus on advancing cancer treatment and improving patient outcomes, Elekta AB (publ) strives to provide state-of-the-art technology and solutions in radiation therapy and radiosurgery. They are committed to developing cutting-edge medical devices and software systems that enable precise and personalized cancer treatment options. Elekta AB (publ) values collaboration, integrity, and a customer-centric approach, ensuring that patients and healthcare professionals have access to the best possible treatment solutions. With a strong global presence, Elekta AB (publ) continues to drive advancements in cancer care worldwide.

Gli analisti fissano attualmente un prezzo obiettivo medio di 56,90 SEK per l’azione Elekta AB (publ) (mediana: 54,06 SEK), pari a -8,2 % rispetto all’ultimo prezzo. Il consenso si basa su 21 giudizi di analisti.

21 analisti valutano attualmente l’azione Elekta AB (publ): 5 raccomandano l’acquisto, 7 la tenuta e 9 la vendita.

Convertita al tasso di cambio attuale, l’azione Elekta AB (publ) quota 5,42 EUR (60,60 SEK).

L’azione Elekta AB (publ) (EKTA B.ST) è quotata su 8 borse, tra cui: London (0O5H.L), Frankfurt (EJXB.F), München (EJXB.MU), Düsseldorf (EJXB.DU), Stockholm (EKTA B.ST).

Elekta AB (publ) is a globally leading company in the development and production of clinical systems for cancer treatment and neurological disorders. The company was founded in 1972 in Stockholm, Sweden, and has been listed on the Stockholm Stock Exchange since 1994. The core business of Elekta includes the planning and delivery of devices and software used in the treatment of cancer and neurological disorders. Elekta offers a variety of products and solutions tailored to the needs of clinics and hospitals worldwide. One of Elekta's main business areas is radiation therapy. The company offers innovative devices such as Elekta's linear accelerators, which generate high-speed particles to target the tumor. Elekta has also developed advanced imaging technology to assist doctors in diagnosis and determining the appropriate treatment method. Another important business area for Elekta is neurological therapy. Here, Elekta has developed devices for accurate diagnosis and treatment of brain tumors, Parkinson's disease, and epilepsy, among others. The offering is complemented by a wide range of software solutions that facilitate treatment planning and monitoring. Elekta works closely with doctors and research institutions to develop innovative solutions that help patients improve their health. Elekta has directed its research and development capacities towards creating new technologies that will further improve cancer treatment in the future. An example is the advanced "Unity" technology, which enables accuracy 30 times higher than conventional radiation. Elekta also has a wide network of service centers to ensure customer support. These facilities provide customers with the solutions they need to facilitate their work and improve patient care. Elekta's business model focuses on the needs of hospitals and clinics worldwide. With its offering of innovative devices and software solutions, Elekta emphasizes quality and technical excellence to meet the needs of customers and patients. The company has gained a global reputation for innovation and outstanding products and is known in the industry for its customer orientation. Overall, Elekta is a leading provider of clinical systems for cancer treatment and neurological disorders. With the continuous development of innovative technologies and products, as well as a strong network of service centers, Elekta is well positioned to consolidate its position in the global health market.

Il fatturato di Elekta AB (publ) ammonta a 16,72 miliardi SEK. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.

Il profitto di Elekta AB (publ) ammonta a -520,00 Mio. SEK. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.

Il rapporto prezzo/utili (P/E) di Elekta AB (publ) è attualmente -44,53. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Elekta AB (publ).

Il rapporto prezzo/fatturato (P/S) di Elekta AB (publ) è attualmente 1,38. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Elekta AB (publ).

Il Quality Score AlleAktien per Elekta AB (publ) è 1/10.

L'ISIN di Elekta AB (publ) è SE0000163628. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.

Il WKN di Elekta AB (publ) è 896279. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.

Il ticker di Elekta AB (publ) è EKTA B.ST. Con questo simbolo di borsa vengono negoziate le azioni Elekta AB (publ) in borsa.

Valore equoTerminal
64,24 SEK
Sopra-/SottovalutazioneTerminal
Correttamente valutato
Settore
Industria
Apparecchiature Sanitarie e Forniture
Numero di azioni
Dipendenti
Ricavi per dipendente
4,08 Mio. SEK
Crescita ricavi Ø 5 anni
Crescita EBIT Ø 5 anni
Crescita dell'utile netto Ø 5 anni
Sito web elekta.com
Paese
Svezia
Valuta
SEK
Offerta pubblica iniziale
1 mar 1994
ISIN
SE0000163628
CUSIP
W2479G107
SEDOL
B0M42T2
Capitalizzazione di mercato
Intervallo 52 settimane
AAQS
1 / 10
Rapporto PEG
-5,08
Rapporto P/E
P/Ee 2027
15,27
P/Ee 2028
14,27
P/Ee 2029
11,99
P/Ee 2030
10,91
P/V
P/Ve
1,34
EV/EBIT
62,90
Rapporto P/B
3,26
ROE (Ritorno sul capitale proprio)
ROA (Ritorno sugli attivi)
ROCE (Ritorno sul capitale investito)
ROIC (Ritorno sul capitale investito)
-3,60 %
Dividendo
Rendimento da dividendi
3,96 %
Rendimento da dividendi stimato
3,96 %
Rapporto di distribuzione
185,44 %
Crescita dividendi Ø5Y
0,85 %
Dividendi per anno
2
Dividendo pagato dal
21 anni
Dividendo non ridotto dal
9 anni
Dividendo aumentato dal
0 anni
Imposta sulla ritenuta del dividendo
30,00 %
Ultimo aggiornamento 21 nov 2026, 11:16

Elekta AB (publ) Ticker

DÜSSELDORF · EJXB.DUFRANCOFORTE · EJXB.FIOB · 0O5H.ILLONDON · 0O5H.LMONACO · EJXB.MUOTC · EKTAFSTOCCOLMA · EKTA-B.STSTOCCOLMA · EKTA B.ST

Elekta AB (publ) FIGI

EKTAB:SS · BBG000BH56D6EJXB:GR · BBG000BT6DC5EJXB:GF · BBG000BT6DN3EJXB:GD · BBG000BT6DT7EJXB:GS · BBG000BT6FX7EJXB:GM · BBG000BT6GB9EJXB:GB · BBG000BT6GY4EJXB:GI · BBG000BT6HX3EKTAF:US · BBG000BT9TS0EKTAF:UV · BBG000BTB3L1EKTAB:EO · BBG000K4GXR9EKTAB:XH · BBG000K4H0D5